Hongying Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hongying Gao has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yu Rao
Tsinghua University
3 shared publications Yonghui Sun
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, 100084, Beijing, China
2 shared publicationsYue Wu
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, 100084, Beijing, China
2 shared publications- Chunsheng Han
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
1 shared publication - Chunwei Zheng
RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, USA
1 shared publication Chunxiao Du
Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, China
1 shared publication
Latest Publications
- 13 May 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 220, 109110
Retinitis pigmentosa 2 pathogenic mutants degrade through BAG6/HUWE1 complex
- 13 May 2022
- Published by Elsevier in Experimental Eye Research
- Vol. 220, 109110
Retinitis pigmentosa 2 pathogenic mutants degrade through BAG6/HUWE1 complex
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 11 (7) , 534-539
FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
Dear Editor,
- 1 July 2020
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 11 (7) , 534-539
Open AccessFAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
Dear Editor,
- Top Cited Papers
- 12 March 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (3) , 237-240
PROTAC Technology: Opportunities and Challenges
PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.
- 12 March 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (3) , 237-240
Top Cited PapersPROTAC Technology: Opportunities and Challenges
PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.
- 8 October 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (10) , 1855-1862
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
Focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase, exerts kinase-dependent enzymatic functions and kinase-independent scaffolding functions, both of which are crucial in cancer development, early embryonic development, and reproduction. However, previous efforts for FAK blocking mainly focus on kinase inhibitors. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that allow direct post-translational knockdown of proteins via ubiquitination of a target protein by E3 ubiquitin ligase and subsequent proteasomal degradation. Here, we designed and synthesized a FAK PROTAC library with FAK inhibitor (PF562271 or VS6063) and CRBN E3 ligand. A novel FAK-targeting PROTAC, FC-11, showed a rapid and reversible FAK degradation with a picomolar of DC50 in various cell lines in vitro, which imply that FAK-PROTACs could be useful as expand tools for studying functions of FAK in biological system and as potential therapeutic agents.
- 8 October 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (10) , 1855-1862
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
Focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase, exerts kinase-dependent enzymatic functions and kinase-independent scaffolding functions, both of which are crucial in cancer development, early embryonic development, and reproduction. However, previous efforts for FAK blocking mainly focus on kinase inhibitors. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that allow direct post-translational knockdown of proteins via ubiquitination of a target protein by E3 ubiquitin ligase and subsequent proteasomal degradation. Here, we designed and synthesized a FAK PROTAC library with FAK inhibitor (PF562271 or VS6063) and CRBN E3 ligand. A novel FAK-targeting PROTAC, FC-11, showed a rapid and reversible FAK degradation with a picomolar of DC50 in various cell lines in vitro, which imply that FAK-PROTACs could be useful as expand tools for studying functions of FAK in biological system and as potential therapeutic agents.